Secura Bio
↗Las Vegas, USA
Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies. Established in 2019, the company focuses on acquiring and advancing late-stage or approved oncology assets to ensure they reach the patients who need them most.
The company's portfolio is anchored by two key assets: Copiktra (duvelisib), a first-in-class dual inhibitor of PI3K-delta and PI3K-gamma, and Farydak (panobinostat), an HDAC inhibitor. Secura Bio is actively expanding the clinical utility of these therapies through ongoing trials in various hematologic malignancies, particularly T-cell lymphomas.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$10M-$50M
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
Total Raised:$215M
Investors:Athyrium Capital Management
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:36
Trial Phases:Phase 1: 5 | Phase 2: 12 | Phase 3: 1 | Phase 4: 2
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Secura Bio Limited (Ireland)
Key Partnerships:CSPC Pharmaceutical Group (China rights for duvelisib), Verastem Oncology (Asset acquisition), Novartis (Asset acquisition)
COMPETITION
Position:Niche Player
Competitors:Gilead Sciences (Zydelig), Novartis (Piqray), Bayer (Aliqopa), Roche, Celcuity
LEADERSHIP
Key Executives:
Joseph M. Limber - CEO
Will Brown - CFO
Dr. Christiane Langer - SVP, Clinical and Medical Affairs
Board Members:Jeffrey A. Stafford, Laurent Arthaud
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Secura Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Secura Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.